ClinicalTrials.gg
Not yet recruitingNCT07846852INSUDIETCOOPUpdated Sep 29, 2026

Impact of Dietary Intervention Within an Interprofessional Cooperative Protocol for Prandial Insulin Dose Adjustment in People Living With Type 1 Diabetes

An observational study in Diabetes Mellitus, Type 1, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 2 sites in France. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
163
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Diabetes Mellitus, Type 1 by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 6 under way, 2 of them phase 3. Diabetes Mellitus, Type 1 · Assistance Publique - Hôpitaux de Paris.

Started
2026
with 1 other
Observational
5 of 23
2 open now
Registered
21st of 23
by date

Among the 23 studies in Diabetes Mellitus, Type 1 by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2026, is one of 5 observational ones, and was the 21st registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

5 of the 23 studies in Diabetes Mellitus, Type 1 by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Diabetes Mellitus, Type 1 by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

This retrospective multicenter cohort study aims to evaluate the effectiveness of an interprofessional cooperative protocol allowing dietitians to adjust prandial insulin-to-carbohydrate ratios in adults living with type 1 diabetes receiving functional insulin therapy. Glycemic outcomes will be assessed using continuous glucose monitoring data collected during routine clinical care. The primary endpoint is the change in Time in Range (TIR) between baseline and 6 months.

Read the detailed description

Type 1 diabetes requires continuous adjustment of insulin doses according to carbohydrate intake. In France, an interprofessional cooperation protocol implemented in 2023 authorizes trained dietitians to adjust insulin-to-carbohydrate ratios under physician supervision.

This retrospective multicenter cohort study will evaluate whether this organization improves glycemic control in routine clinical practice. Data will be collected from medical records and glucose monitoring platforms without modifying patient management.

The primary outcome is the difference in Time in Range (0.70-1.80 g/L) between baseline (M0) and Month 6 (M6). Secondary outcomes include differences in hypoglycemia, hyperglycemia, glucose variability and Glucose Management Indicator (GMI) assessed between baseline and follow-up visits at Month 3 and Month 6.

03

Conditions studied

  • Diabetes Mellitus, Type 1

Keywords

  • Interprofessional cooperative protocol
  • Prandial insulin
  • Type 1 diabetes
  • Dietitian
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged 18-69 years with type 1 diabetes or insulin-deficient diabetes receiving routine care under an interprofessional cooperation protocol for prandial insulin dose adjustment. Eligible participants must have had diabetes for more than 6 months, be treated with multiple daily insulin injections or an insulin pump, and have completed structured education in functional insulin therapy. Patients with unstable proliferative retinopathy, pregnancy, other types of diabetes, temporary treatments affecting insulin requirements, legal protection measures, or who object to the use of their data are excluded

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18 to 69 years.
  • Receiving routine clinical care under an interprofessional cooperation protocol for prandial insulin dose adjustment (protocol implemented since January 1, 2023).
  • Living with type 1 diabetes mellitus or insulin-deficient diabetes, confirmed by the presence of anti-GAD, anti-IA2, anti-ZnT8, or insulin autoantibodies, and requiring optimization of insulin therapy.
  • Diabetes duration greater than 6 months.
  • Treated with multiple daily insulin injections or an insulin pump (open-loop or hybrid closed-loop system).
  • Completion of a structured therapeutic education program in functional insulin therapy (individual consultations and/or educational workshops).
  • Able to understand study information and procedures.

Exclusion criteria

Exclusion Criteria:

  • Unstable severe proliferative diabetic retinopathy.
  • Any type of diabetes other than type 1 diabetes or insulin-deficient diabetes.
  • Pregnant women with type 1 diabetes.
  • Current treatment with temporary therapies that may affect insulin requirements (e.g., chemotherapy or systemic therapy).
  • Individuals under legal guardianship, curatorship, or any other legal protection measure.
  • Objection to the use of personal data for research purposes
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
163 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients receiving routine care under a cooperation protocol for prandial insulin adjustment

    Other: Routine care data collection

Interventions

  • OtherRoutine care data collection

    Data collection from patients receiving standard care under a cooperation protocol for prandial insulin dose adjustment, with data collected from patients' medical records and glucose monitoring platforms without modifying patient management

06

What researchers measure

Primary outcomes

  1. Difference in Time in Range (0.70-1.80 g/L) between baseline (M0) and Month 6 (M6)

    Time frame: Baseline and 6 months

Secondary outcomes

  1. Difference in time spent in the glycemic target range (Time in Range, TIR between 0.70 g/L and 1.80 g/L) between M3 and M0

    Time frame: Baseline and 3 months

  2. Difference in time spent in hypoglycemia (Time Below Range, TBR < 0.70 g/L) between M3 and M0 and between M6 and M0

    Time frame: Baseline, 3 months and 6 months

  3. Difference in time spent in severe hypoglycemia (Time Below Range, TBR < 0.54 g/L) between M3 and M0 and between M6 and M0

    Time frame: Baseline, 3 months and 6 months

  4. Difference in time spent in hyperglycemia (Time Above Range, TAR > 1.80 g/L) between M3 and M0 and between M6 and M0

    Time frame: Baseline, 3 months and 6 months

  5. Difference in time spent in severe hyperglycemia (Time Above Range, TAR > 2.50 g/L) between M3 and M0 and between M6 and M0

    Time frame: Baseline, 3 months and 6 months

  6. Difference in glucose variability coefficient between M3 and M0 and between M6 and M0

    Time frame: Baseline, 3 months and 6 months

  7. Difference in Glucose Management Indicator (GMI) between M3 and M0 and between M6 and M0

    Time frame: Baseline, 3 months and 6 months

07

Study locations

2 sites
  • Service de diabétologie, Hôpital Lariboisière - AP-HP
    Paris, France
  • Service de nutrition - diabétologie, Hôpital Européen Georges Pompidou - AP-HP
    Paris, France
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared

Supporting information: Study protocol, Informed consent form

Time frame: Two years after the last publication

Access criteria: Data sharing must be accepted by the sponsor and the PI based on a scientific project and scientific involvement of the PI team. Collaboration will be fostered. The founder could be involved in the decision. Teams wishing obtain IPD must meet the sponsor and IP team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization. Processing of shared data must comply with European General Data Protection Regulation (GDPR).

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Apr 2028, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartEst.
Oct 2026
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846852
Collaborators
GIRCI IDF
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Oct 2026 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Youcef Sekour
Contact
youcef.sekour@aphp.fr
+33156095823
Virginie Lafaille
principal investigator · Service de nutrition - diabétologie, Hôpital Européen Georges Pompidou - AP-HP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion